Description: Can-Fite BioPharma, Ltd., a biotechnology company, develops drugs for the treatment of cancer and autoimmune inflammatory diseases. The company principally develops CF101 that is in Phase III study for the treatment of psoriasis; and has completed Phase II study for the treatment of rheumatoid arthritis and glaucoma, as well as completed Phase III study for the treatment of dry eye and Phase I study for the treatment of uveitis. It also develops CF102, which is in Phase II study for the treatment of hepatocellular carcinoma; and CF602 that has completed pre-clinical trial for the treatment of inflammatory diseases. The company was founded in 2000 and is based in Petach Tikva, Israel.
Home Page: www.canfite.com
CANF Technical Analysis
10 Bareket Street
Petah Tikva,
4951778
Israel
Phone:
972 3 924 1114
Officers
| Name | Title |
|---|---|
| Dr. Pnina Fishman Ph.D. | Scientific Founder, CEO & Director |
| Mr. Motti Farbstein | Chief Operating & Financial Officer |
| Dr. Sari Fishman Ph.D. | VP of Bus. Devel. |
| Dr. Ilan Cohn Ph.D. | Co-Founder & Chairman |
| Dr. Vibeke Strand FACP, FACR, FACR (USA), M.D. | Sr. Clinical Advisor |
Exchange: NYSE MKT
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.7089 |
| Price-to-Sales TTM: | 25.8032 |
| IPO Date: | 2012-11-06 |
| Fiscal Year End: | December |
| Full Time Employees: | 8 |